Home / Blog

DelveInsight Blog

Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.

Search by Categories

Ravulizumab Outshines Competitors: Insights from NMOSD Treatment Analysis

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. In comparison to other therapeutic options, ravulizumab stands out as a symbol of pioneering progress and efficacy, surpassing competitors with its remarkable reduction in relapse risk and promising outcomes for patients with NMOSD. In the tapestry of autoimmune diseases, NMOSD emerges as a formidable adversary, wreaking havoc on the central nervous system (CNS). Amidst the arsenal of approved therapies, the quest…
ravulizumab-nmosd-treatment-analysis

Riliprubart’s Ascendancy: Phase II Results Illuminate Path Forward for CIDP Treatment

Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to selectively target the serine protease C1s, in pursuit of its potential therapeutic application in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Riliprubart unveils compelling efficacy in CIDP treatment, fostering improvement among Standard-of-Care (SOC)-Treated participants and igniting a resurgence in SOC-Refractory individuals, accompanied by notable enhancements in disability measures and a reduction in plasma neurofilament light chain. In the labyrinth of CIDP, where demyelination and inflammation entwine to ensnare the afflicted, complement activation emerges as a malevolent orchestrator…
riliprubart-phase-ii-results

Leading the Charge: ULTOMIRIS’s Impact on NMOSD Relapse Prevention Strategies

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. The remarkable reduction in relapse risk observed in the CHAMPION-NMOSD trial serves as a beacon, illuminating ULTOMIRIS's transformative potential in charting a new course for patients navigating the complexities of NMOSD. Recently on 25th March 2024, ULTOMIRIS (ravulizumab-cwvz) was approved in the United States for the treatment of adult patients with anti- AQP4 Ab+ NMOSD. ULTOMIRIS is also approved for certain…
ultomiris-phase-iii-champion-nmosd-trial

Trending

semaglutide-phase-iii-pioneer-sustain-and-step-trial
Semaglutide: Unveiling Hope for Alzheimer’s Disease Patients

Semaglutide provides a potential therapeutic avenue for aging-related neurodegenerative diseases, such as Alzheimer's disease through…

Find out more
prx012-and-prx123-for-alzheimers-disease
Prothena’s Promise: Revolutionizing Alzheimer’s Treatment with a ...

PRX012, a next-generation subcutaneous antibody, has the potential to eliminate treatment obstacles due to its…

Find out more
donanemab-phase-iii-trailblazer-alz-2-trial
Brighter Tomorrows: Donanemab’s Role in Elevating Patient and Clinician...

Donanemab, with improved safety, efficacy, convenient dosing regime, and most importantly its ability to not…

Find out more
smart-pills-future-outlook
From Science Fiction to Reality: Investigating the Market Dynamics and Growin...

Over the past few years, the evolution of Smart Pills has been remarkable, driven largely…

Find out more
pharma-news-for-ipsen-synox-roche-abbvie
Ipsen and Skyhawk Therapeutics Partnership; SynOx Therapeutics’ Phase III Tri...

Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk…

Find out more
rezdiffra-journey-in-nash-treatment
Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment

Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges.…

Find out more

Artificial Intelligence (AI) in Mental Health
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

FDA granted accelerated approval to Lilly’s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.

Find More
dermatomyositis-treatment

Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives

Read More
stelara-biosimilar-wezlana

Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

Read More
Cryotherapy Market Analysis

Navigating the Booming Cryotherapy Market and Its Future Outlook

Read More
label-expansion-of-xtandi-and-keytruda

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

Read More

voquezna-for-gerd-treatment
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Find More
recent-developments-in-nsclc-treatment
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Find More
Rehabilitation Equipment Market Analysis
Evaluating the Growing Role of Rehabilitation Equipment in Revitalizing Lives and Improving the Treatment Outcome

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone ...

Find More

Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

Find More
Product Assessment
Product Assessment

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

Find More
Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Find More
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

Find More
In Licensing Opportunity
In-Licensing Opportunity

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

Find More
Go To Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

Find More

See How We Do It

Our Consulting Services
Consulting Services

Optimized, competent, and dependable solutions to tackle fast-paced pharma market challenges.

Our Pharma Market Reports
Pharma Market Reports

Credible, data-driven, & analytical pharma & biotech market research & analysis for a holistic understanding.

Our MedTech Insights
MedTech Insights

Clinical solutions for vastly expanding diagnostics, digital therapeutics, & the MedTech industry.